<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="808">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05150639</url>
  </required_header>
  <id_info>
    <org_study_id>IVF-2</org_study_id>
    <nct_id>NCT05150639</nct_id>
  </id_info>
  <brief_title>Vaginal Microbiome and IVF Pregnancy Outcome</brief_title>
  <official_title>Associations Between the Vaginal Microbiome, Inflammatory Status and Pregnancy Outcome - a Prospective, Observational Study in Women Undergoing Frozen Embryo Transfers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Freya Biosciences ApS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston IVF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Freya Biosciences ApS</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective, observational study is to investigate the prevalence of vaginal&#xD;
      dysbiosis among women undergoing IVF procedures in the US. And to investigate the&#xD;
      associations between the vaginal microbiome and the pregnancy outcome following IVF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study will evaluate differences in vaginal microbiome composition in pregnant and&#xD;
      non pregnant women who have undergone IVF treatment with frozen embryo transfer. Concurrently&#xD;
      we aim to identify whether menstrual tissue and Cervicovaginal secretion possess&#xD;
      complimentary biomarker information reflecting the immune/inflammatory status of the&#xD;
      reproductive tract to determine its impact on pregnancy success following frozen embryo&#xD;
      transfer IVF procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of vaginal dysbiosis</measure>
    <time_frame>Evaluated from sample collected 1 week prior to frozen embryo tranfer</time_frame>
    <description>The prevalence (evaluated as % of included population) of vaginal dysbiosis in women undergoing frozen embryo tranfer IVF treatment in the US</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Associations of microbiome</measure>
    <time_frame>Evaluated from sample collected 1 week prior to frozen embryo tranfer and correlated with pregnancy outcomes obtained up until birth</time_frame>
    <description>The difference in pregnancy success rates (biochemical pregnancy, clinical pregnancy and live birth) following frozen embryo transfer in women with versus without vaginal dysbiosis</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Vaginal Flora Imbalance</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IVF</intervention_name>
    <description>Women planning to undergo frozen embryo transfer IVF precedure will be included. Samples will be obtained, but no study intervention will be applied. Pregnancy outcome data will be obtained, following frozen embryo transfer, to correlate agains other data from samples (vaginal microbiome etc).</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples collected will be:&#xD;
&#xD;
      Vaginal swabs Vaginal secretion Urine Menstrual effluent (optional) Peripheral blood&#xD;
      (optional)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women planning to undergo frozen embryo transfer IVF treatment at Boston IVF fertility&#xD;
        clinic in Boston, US.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-44 years&#xD;
&#xD;
          -  Patients whose written informed consent approved by the Institutional Review Board&#xD;
             (IRB) has been obtained, after having been duly informed of the nature of the study&#xD;
             and voluntarily accepted to participate after being fully aware of the potential&#xD;
             risks, benefits and any discomfort involved.&#xD;
&#xD;
          -  Women undergoing a planned frozen embryo transfer&#xD;
&#xD;
          -  BMI between 18.5-35 kg/m2 (both included)&#xD;
&#xD;
          -  Must be able to understand and read the informed consent form in English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current diagnosis of pathologies or malformations that affect the uterine cavity such&#xD;
             as polyps, intramural myoma, adhesions, fibroids or hydrosalpinx.&#xD;
&#xD;
          -  Any illness or medical condition that is unstable or which, according to medical&#xD;
             criteria and Investigator's discretion may put at risk the patient's safety and her&#xD;
             compliance in the study.&#xD;
&#xD;
          -  Participants currently taking antibiotics or with any known condition requiring&#xD;
             regular use of antibiotics, that would suggest the participant is likely to need&#xD;
             antibiotic treatment during the observational period of this study.&#xD;
&#xD;
          -  Systemic and/or vaginally applied antibiotic use within the last month prior to&#xD;
             screening (except for prophylactic antibiotics related to egg retrieval).&#xD;
&#xD;
          -  Patients utilizing OCPs in the past month&#xD;
&#xD;
          -  Latex or silicone allergy (Diva Cup and Vaginal Disc)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Vaughan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston IVF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denny Sakkas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston IVF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristin Rooney</last_name>
    <phone>4346470</phone>
    <phone_ext>781</phone_ext>
    <email>kRooney@bostonivf.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Denny Sakkas, PhD</last_name>
    <phone>4346500</phone>
    <phone_ext>781</phone_ext>
    <email>DSakkas@BOSTONIVF.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston IVF The Waltham Center</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kristin Rooney</last_name>
      <phone>781-434-6470</phone>
      <phone_ext>781</phone_ext>
      <email>kRooney@bostonivf.com</email>
    </contact>
    <contact_backup>
      <last_name>Denny Sakkas, PhD</last_name>
      <phone>7814346500</phone>
      <phone_ext>781</phone_ext>
      <email>DSakkas@BOSTONIVF.com</email>
    </contact_backup>
    <investigator>
      <last_name>Denny Sakkas, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Vaughan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 26, 2021</last_update_submitted>
  <last_update_submitted_qc>November 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

